Retrophin Inc (NASDAQ:RTRX) SVP Elizabeth E. Reed sold 942 shares of the company’s stock in a transaction on Friday, January 5th. The shares were sold at an average price of $24.04, for a total value of $22,645.68. Following the completion of the transaction, the senior vice president now directly owns 9,058 shares in the company, valued at approximately $217,754.32. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Retrophin Inc (NASDAQ RTRX) opened at $23.18 on Thursday. Retrophin Inc has a 12 month low of $15.55 and a 12 month high of $26.44. The company has a current ratio of 3.88, a quick ratio of 3.83 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $894.00, a PE ratio of -17.56 and a beta of 1.45.

Retrophin (NASDAQ:RTRX) last posted its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.25) by ($0.21). Retrophin had a negative return on equity of 10.13% and a negative net margin of 33.79%. The firm had revenue of $40.34 million for the quarter, compared to analyst estimates of $40.51 million. During the same period in the previous year, the company posted ($0.09) EPS. Retrophin’s revenue was up 18.8% on a year-over-year basis. analysts forecast that Retrophin Inc will post -1.25 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Perceptive Advisors LLC lifted its stake in Retrophin by 0.5% during the 3rd quarter. Perceptive Advisors LLC now owns 2,686,204 shares of the biopharmaceutical company’s stock worth $66,859,000 after acquiring an additional 13,895 shares in the last quarter. Vanguard Group Inc. lifted its stake in Retrophin by 8.3% during the 2nd quarter. Vanguard Group Inc. now owns 1,635,234 shares of the biopharmaceutical company’s stock worth $31,707,000 after acquiring an additional 125,695 shares in the last quarter. Macquarie Group Ltd. lifted its stake in Retrophin by 22.7% during the 3rd quarter. Macquarie Group Ltd. now owns 1,459,218 shares of the biopharmaceutical company’s stock worth $36,320,000 after acquiring an additional 270,399 shares in the last quarter. Oak Ridge Investments LLC lifted its stake in Retrophin by 96.9% during the 2nd quarter. Oak Ridge Investments LLC now owns 1,022,871 shares of the biopharmaceutical company’s stock worth $19,833,000 after acquiring an additional 503,428 shares in the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in Retrophin by 8.7% during the 3rd quarter. Dimensional Fund Advisors LP now owns 896,815 shares of the biopharmaceutical company’s stock worth $22,322,000 after acquiring an additional 71,562 shares in the last quarter.

Several equities analysts have recently commented on the company. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered Retrophin from a “hold” rating to a “strong sell” rating in a research note on Tuesday, November 14th. BMO Capital Markets reaffirmed a “buy” rating and issued a $44.00 price target on shares of Retrophin in a research note on Friday, October 6th. Finally, ValuEngine lowered Retrophin from a “hold” rating to a “sell” rating in a research note on Monday, November 20th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus price target of $44.00.

COPYRIGHT VIOLATION NOTICE: This report was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://www.thecerbatgem.com/2018/01/11/retrophin-inc-rtrx-svp-elizabeth-e-reed-sells-942-shares.html.

Retrophin Company Profile

Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).

Receive News & Stock Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related stocks with our FREE daily email newsletter.